This study shows that RNA decay rather than the presence of premature termination codons triggers a TA-like response.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...

The company's blood disorders treatment -- Casgevy -- also is a multibillion-dollar opportunity, according to Vertex. The drug launch unfolded last year, and since treatment involves a lengthy ...

If you’re looking for information about Insider Program previews for upcoming feature releases of Windows 10, see “Windows 10 Insider Previews: A guide to the builds.” The update has a wide ...

The skies are brighter, and the air is beginning to feel a tad warmer… So, we’re introducing our guide for spring in Lancaster, with activities and all you need to know, to have the perfect ...

"The Wheel of Time" season 3 is finally here this week. "The Rings of Power" season 2 has been and gone, meaning we're now looking ahead to Prime Video's other major fantasy saga. The show was ...

The team first focused on a structural feature of the CRISPR Cas9 protein that is key to its success as a genome-editing tool; this structural feature is responsible for binding to the enzyme’s RNA ...

Getting into golf might seem intimidating, but it shouldn’t be. The golf course is a great place to learn a fun game that will not only allow you to get great exercise but learn valuable skills ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...

Optum Rx, is the pharmacy benefit manager owned by UnitedHealth Group Inc’s UNH Also Read: HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is ...